InvestorsHub Logo
Followers 57
Posts 5700
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Thursday, 12/16/2021 12:10:30 AM

Thursday, December 16, 2021 12:10:30 AM

Post# of 14947
Does Big Pharma have many resources to do a deal with Sorrento centered on ABIVERTINIB? I just read this about the potential for 2020 being a record year for M&A...$500 billion in cash and $1.7 trillion in leveraged assets can do a lot of deals! Partnerships and buyouts will abound IMO.

"Merger and acquisition activity has been rather slow in the biopharma industry so far this year. But, by one team of analysts’ calculations, large drugmakers will have big piles of cash to deploy in 2022.

Eighteen large-cap U.S. and European biopharmas will have more than $500 billion in cash on hand by the end of 2022, SVB Leerink analyst Geoffrey Porges and his team wrote in a Wednesday note. The companies could use the money to strike deals, pay down debt or offer returns to shareholders through dividends or share buybacks, the analysts said.

Because the companies can leverage their assets to borrow additional capital, the theoretical firepower of the 18 drugmakers would be enormous at more than $1.7 trillion, the analysts wrote..."

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRNE News